Other than ibrutinib, people with M-CLL, devoid of TP53 aberrations and in good shape enough to tolerate FCR therapy, should still be very good candidates with the latter, Along with the gain being this treatment method is often finished in 6 months although ibrutinib has to be taken indefinitely. This selection could be specially precious for non-